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Bacillus Calmette-Guérin immunization in infants born 
to HIV-I-seropositive mothers 
Sophie Lallemant-Le Coeur, Marc Lallemant?, Dominique Cheynied, 
Samuel Nzingoula?, Jacques Druckerz and Bernard Larouze 
During the prospective follow-up of 64 babies at risk for perinatal HIV-1 infection 
because their mothers were, seropositive, and of 130 control babies whose 
mothers were seronegative, we studied the occurrence of complications of bacillus 
Calmette-Cuérin (BCC) immunization and its ability to induce cutaneous reactivity to 
tuberculin. Babies born both to HIV-I-positive and HIV-I-negative mothers received 
BCC immunization during their first month of life according to the Expanded 
Programme on Immunization (EPI) recommendations. Local and regional complications 
of BCG vaccine were looked for at 3,6 and 9 months after inoculation. A tuberculin skin 
test was performed at 6 or 9 months of age. Most babies born to HIV-I-positive mothers 
were later classified as infected or uninfected according to their clinical condition 
and/or serological status at 18 months of age. The mean duration of the follow-up was 
. 36 months (range 30-40 months). No chronic or deep ulcerations at the site of injection 
or disseminated forms of BCC infection were observed. The frequency of BCC-related 
lymphadenitis in the group of HIV-I-infected children (24%) did not differ significantly 
from the group of uninfected children (19%; Fisher test: P = 0.73). In cohtrast, the 
tuberculin skin test responses were positive less often in the group of HIV-I-infected 
children (33%) than in the uninfected group (83%; Fisher test: P = 0.007). Because 
BCC vaccine appears to be safe - even when given to perinatally infected babies 
- continuation of the BCC immunization policies of the EPI is justified, especially in 
view of the growing incidence of tuberculosis as a complication of HIV infection. 
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Introduction I 
Tuberculosis is of major public health importance in 
Africa and is becoming an even greater problem because 
of its exacerbation by the HN epidemic [1,2]. In areas 
were tuberculosis is endemic, bacillus Calmette-Guérin 
(BCG) immunization at birth is still the basic method 
for tuberculosis prevention [ 3-51. Fatal complications 
of BCG immunization have been reported in infants 
with congenital immunodeficiency [ 6,7], and case reports 
have raised doubts about the safety of BCG in HIV: 
1-infected infants because of their impaired immunity 
[t3-13]. In addition, the presence of HIV-related immuno- 
deficiency might decrease the response to tuberculin anti- 
gen and the accompanying protective effect of BCG im- 
munization [ 1 4 3  J. 
To date, no published study in infants has given prospec- 
tive data concerning the effect of BCG inlmunization in 
the setting of HIV infection. The present investigation was 
designed within an established prospective cohort study 
on mother-child transmission of HIV infection [ 16 J.  The 
objective of our investigation was to evaluate both the oc- 
currence of locoregional complications of BCG inocula- 
tion at birth, and the induction of subsequent tuberculin 
reactivity in HIV:l-infected and uninfected infants bom 
to seropositive mothers and in control infants bom to 
seronegative mothers. 
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Subjects and methods 
Pregnant women were recruited sequentially, after giv- 
ing informed consent, during their first prenatal visit to 
one of two mother-child clinics serving the eastern dis- 
tricts of Brazzaville, Congo. Sera were tested for anti- 
bodies to HN-1 by enzyme-linked immunosorbent as- 
say (EUS4 ELAVIA, Diagnostics Pasteur, Marnes-La-Co- 
quette, France). Positive ELISA tests were confirmed by 
Westem blot (Blot test, Du Pont de Nemours, W W g -  
ton, Delaware, USA). Sera were considered positive when 
they showed antibodies to at least two envelope &CO- 
proteins of HIV-1. 
Each seropositive woman was individu@ matched for 
age, estimated date of delivery, and place of residence 
(district) with two seronegative pregnant women. Mer 
birth, infants were followed with clinical examination and 
blood sampling by the same physician at 1 month, 3 
months, and every 3 months thereafter (active follow- 
up included home visit for individuals not presenting for 
scheduled visits). The mean duration of the follow-up 
was 36 months (range 30-40 months). 
Babies bom to both seropositive and negative moth- 
ers received BCG immunization (Pasteur Vacdns, strain 
1173P2, Diagnostics Pasteur) during their first month of 
life according to the World Health Organization (WHO) 
recommendations: 0.05 mg in 0.05 ml via intradermal in- 
jection on the lateral surface of the left arm [171. 
The infants were examined for local and regionat com- 
plications of BCG immunization at 3, 6 and 9 months 
after inoculation. holated left arrillary and/or supraclav- 
icular lymph nodes >Icm in diameter, without other 
discernible local cause, were considered to be related to 
BCG. 
A tuberculin skin test (Monotest, Mérieux, Lyon, France; 
intradermal route by multipuncture of tuberculin anti- 
gen at a dose of 300 O00 IU/ml) was performed at 6 or 
9 months of age. The delayed hypersensitivity response 
to tuberculin was reported by the same physician 48 h 
later. A positive skin reaction was delined as an area of 
induration with a diameter > 2 mm [l8]. 
The 178 babies on whom follow-up studies are avail- 
able were subdivided into four groups. Group 1: HIV- 
1-infected infants who had AIDS according to the WHO 
clinical surveillance definition and/or who were seroposi- 
tive at 18 months of age or older; group 2: HN-l-indeter- 
minate infants whose clinical status did not fit the AIDS 
definition or who were younger than 18 months; group 
3: HIV-1-uninfected infants, i.e. those who were seroneg- 
ative after 18 months of age, and group 4: inFants bom 
to seronegative mothers. 
Statistical analyses ( x 2  test, Fisher's exatt two-tded test, 
and Student's t-test) were performed using BMDP Statis- 
tical Software [ 191. Statistical signisCance was designated 
at P < 0.05. 
Results 
F~fty-two f the 64 infants bom to seropositive mothers 
(81%) and 127 out of 130 infants bom to seronegative 
mothers (98%) were vaccinated by BCG and could be 
traced for more than 3 months. The other babies were ei- 
ther lost to follow-up (one bom to a seropositive mother 
and one to a seronegative) or had died (11 had sero9si- 
tive and two had seronegative mothers). Causes of death 
are shown in Table 1. 
Table 1. Causes of death among the infants before 6 months of age. 
Cause of death 
Mothers 
HIV + HIV - 
Prematurity or hypotrophy 5 2 
Acute respiratory infection 5 . o  
AIDS 6 O 
Unknown cause 2 1 
Total 18 3 
No chronic or deep ulcerations were observed at the 
site of injection of BCG. The frequency of BCG-related 
lymphadenitis (Table 2) was similar in infants bom to 
seropositive and to seronegative mothers: 21% (11 out of 
52) versus 18% (23 out of 1271, respectively (xi = 0.22, 
not signiíïcant). Among the infants born to seroposi- 
tive mothers, the frequency of BCG-related lymphadenitis 
was similar in m-1-infected infants (group 1) to that in 
uninfected infants (group 3): 24% (five out of 21) versus 
19% ( h e  out of 27; Fisher test, P = 0.73). 
Table 2. Frequency of bacillus Calmette-Cuérin-related adenitis accord- 
inE to HIV-1 status of infant. 
~ ~ 
Group 1 Group 2 Group 3 Group 4 
infants infants infants infants 
n WO) n WO) n (%I n (010) 
Lymphadenitis present 5 (24) 1 (25) 5 (19) 23 (18) 
Lymphadenitis absent 16 (76) 3 05) 22 (81) 104 (82) ~ 
Total 21 (100) 4 (100) 27 (100) 127 (100) 
Group 1 infants, infants with AIDS or HW-I-seropositive at 18 months of 
age; group 2 infants, HIV-I-indeterminate infants of HIV-I-infected moth- 
ers; group 3 infants, HIV-I-uninfected infants of HIV-I-infected mothers; 
group 4 infants, HIV-1-uninfected infants of uninfected mothers. Group (1 
+ 2 + 3) versus (41, x2 = 22, P = 0.63 (NS); group (1) versus (3), Fisher ex- 
act test P = 0.73 (NS); group (1) versus (3 + 4), Fisher exact test P = 0.55 
(NS). 
Lymphadenitis, ikluding one case with a fistula in an 
infant bom to a seronegative mother, resolved sponta- 
neously in all instances. 
No disseminated forms of BCG infection were detected 
during the follow-up period. 
Results of the tuberculin skin tests were available for 36 
infants bom to seropositive mothers (56%) and 105 in- 
fants bom to seronegative mothers (81%). The others 
were lost to follow-up (four infants bom to seropositive 
I 
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Table 3. Frequency of positive tuberculin skin test (> 2") according to 
HIV-1 status of infant. 
Group 1 Group 2 Group 3 Group4 
n WO) n WO) n (%I n WO) 
Skin test >2mm 4 (33) O (O) 19 (83) 88 (84) 
Skin test S2mm 8 (67) 1 (100) 4 (17) 17 (16) 
Total 12 (100) I (100) 23 (100) 105 (100) 
Groups 1 4  as in Table 2. Group (1 + 2 + 3) versus (41, xz = 6.35, P = 0.01; 
group (1) versus (3), Fisher exact test P = 0.007; group (1) versus (3 + 4), 
Fisher exact test P = O.ooo4. 
mothers and six bom to seronegative mothers), did not 
have their skin tests read (six with seropositive and 16 
with seronegative mothers), or had died before the age 
of 6 months (18 and three,#respectively). 
I 
( 
The frequency of positive skin tests (Table 3) was lower 
in infants bom to HIV-1-seropositive mothers than in in- 
fants bom to seronegative mothers: 64% (23 out of 36) 
versus 84% (88 out of 105; x2 = 6.35; P = 0.01). Among 
the infants bom to seropositive mothers, the frequency of 
positive tuberculin tests was even lower among HW-1-in- 
fected infants (group 1) than in uninfected infants (group 
3): 33% (four out of 12) versus 83% (19 out of 23; Fisher 
test: P= 0.007). 
I 
The mean diameter of induration was 4.0" (s.d. = 
2.76) among infants bom to seropositive mothers and 
5.0 mm (s.d. = 2.56) among infants bom to seronegative 
mothers (t-test: 1.96, P = 0,052). Itwas significantly lower 
in HIV-1-infected infants (group 1) than in uninfected in- 
fants (group 3): 2.0" (s.d. = 1.86) versus 5.1 mm (s.d. 
= 2.511, respectively (t-test: 3.80, P = 0.OOOl). Distribu- 
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Fig. 1. Distribution of the tuberculin skin test resljonses according 
to HIV-1 status of infant. U, Croup 1 infants (infants with AIDS 
or HIV-I-seropositive at 18 months of age); El, group 3 infants 
(HIV-I-uninfected infants of HIV-I-infected mothers); O, group 4 
infants (uninfected infants born to HIV-I-seronegative mothers). 
Discussion 
The results from this study show that there was no sig- 
nificant difference in the frequency of BCG-related lyn- 
phadenopathy either in babies bom to HIV-1-seroposi- 
tive or seronegative mothers, or in babies with or without 
HIV-1 infection. In contrast, babies with HN-1 infection 
had less cutaneous reactivity to tuberculin than babies 
without HIV-1 infection. These results provide further in- 
sight into discussions concerning the risks versus benefits 
of BCG immunization as currently recommended by the 
Expanded Programme on Immunization (EPI) in high 
HW prevalence areas [ 171. 
The high frequency (18%) of regional lymphadenitis in 
the overall study population, which is higher than pre- 
viously reported by the Brazzaville Centre for Tubercu- 
losis Control [20], could be attributable to several fac- 
tors: (1) the BCG strain used for immunization is known 
as a 'hot' strain by comparison with the Glaxo or Tokyo 
strain [21]; (2) the systematic and active follow-up of the 
present cohort of vaccinated infants, and (3) the criteria 
for the diagnosis of lymphadenitis (size 2 1 cm), which 
is less stringent than in other studies where only cases of 
abscessed lymphadenitis are considered [ 221, 
The similar frequency of lymphadenitis after BCG inocu- 
lation between infants bom to seropositive and seroneg- 
ative mothers is consistent with the results of studies 
carried out using a longitudinal approach in Zaire [23], 
Kenya [241 and Uganda [25], although the HIV status of 
the babies was not shown. In the present study, the HIV 
status was known for most infants, and this infection was 
not associated with a signiíïcantly higher frequency of lo- 
coregional complications and dissemination was not de- 
tected. 
Serological assessment of 19 babies who were evaluated 
in Kinshasa [22] for BCG-related abscess revealed that 
d were HIV-negative. This finding also emphasizes the 
absence of a relationship between HN serological sta- 
tus and complications of BCG immunization. Five cases 
of suppurative BCG-related adenitis in HIV-1-infected ba- 
bies have been observed in hospitals in France (Griscelli 
C, Blanche S, personal communication), but the fre- 
quency of this complication among all BCG-vaccinated 
babies cannot be evaluated from such uncontrolled re- 
ports. 
Some cases of disseminated BCG infection have been 
reported in HIV-1-infected adults [26,27]. One case has 
been described in an HIV-infected infant from Zaire [ 131. 
The fact that no babies with disseminated BCG infec- 
tion were observed in the Brazzaville study after a mean 
follow-up of 36 months is in agreement with the results 
of similar prospective studies carried out in Zaire [23] 
and Kenya [24]. The estimated risk of disseminated BCG 
infection among babies with severe congenital immuno- 
deficiency is 1% [28]. If one assumes that the same 
high risk of dissemination might be seen in HN-1-re- 
lated immunodeficiency, sufficiently large cohort studies 
are needed in order to detect cases of disseminated BCG 
infection [ 23,241. In the absence of radiological and bac- 
teriological investigations and of postmortem verification, 
.: 
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it is impossible to exclude the occurrence of dissemi- 
nated BCG in the children in the present study who died. 
The circumstances of their deaths, however, do not sup- 
port this diagnosis. As is the case for many HIV-related 
opportunistic infections, a possible reactivation of BCG 
may occur as a late complication of the profound im- 
munological deterioration accompanying HIV infection. 
Accordingly, there is a need for additional investigations 
into the cause of death in HIV-positive babies who die 
after BCG vaccination. 
In the present study, the fact that HW-1 infection in in- 
fants was associated with a lower frequency of positive tu- 
berculin tests suggests the early occurrence of immuno- 
deficiency in infected infants. The percentage of nega- 
tive tuberculin tests among infants might have been un- 
derestimated, since seved of these infants died of con- 
ditions related to HIV-1 immunodeficiency before they 
were skin-tested, and they most likely would have scored 
as tuberculin-negative. Nevertheless, 33% of the HIV-1-in- 
fected infants in whom the response to tuberculin was 
evaluated did develop a positive test and, therefore, might 
have achieved a level of protection against serious com- 
plications of primary tuberculosis [29,30]. 
In HIV-endemic areas in which BCG immunization is uti- 
lized, the HIV-1 serostatus of a mother may be known. 
In this setting, given the particularly high risk of tubercu- 
losis for infants (HIV-1-infected or uninfected) and the 
likelihood of an HIV-seropositive mother having tubercu- 
losis, BCG immunization can be safely performed except 
in symptomatic infànts. The feasibility of routine HN-1 
screening in pregnant women is low virtually everywhere 
in Africa [31], and the diagnosis of HIV-1 infection in 
neonates is not practical [32]. Therefore, immunization 
strategies can be planned only at a population level. From 
the results of the present study, we conclude that the 
EPI policies on BCG immunization [33] should be re- 
inforced in areas where J3V-l infection is highly preva- 
lent because (1) BCG immunization is safe, irrespective 
of the serological status of mothers and infants; (2) the 
risk of tuberculosis is greatly increased in regions such 
as subSaharan Africa where there is a high prevalence of 
both tuberculosis and HIV infection [34-38]; (3) the pro- 
tection conferred by BCG immunization to uninfected 
babies bom to seropositive mothers far outweighs the 
theoretical risk of disseminated infection in HIV-infected 
babies, and (4)  some HIV-infected children (those who 
develop a positive tuberculin skin test) may be transiently 
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